Low dose whole Lung Therapy for patients with SARS-CoV-2 disease (COVID-19) Pneumonitis

Abstract

In this article provides an overview of publications by foreign authors of the novel coronavirus (SARS-CoV-2) and introduce a modified treatment method for COVID-19-associated pneumonia. X-ray therapy was used to treat pneumonia during the first half of the 20th century. Fifteen studies report that approximately 700 cases of bacterial (lobar and bronchopneumonia), sulfanilamide non-responsive, interstitial, and atypical pneumonia were effectively treated by low doses of X-rays, leading to disease resolution, based on clinical symptoms, objective disease biomarkers, and mortality incidence. The capacity of the X-ray treatment to reduce
mortality was similar to serum therapy and sulfonamide treatment during the same time period. The mechanism by which the X-ray treatment acts upon pneumonia involves the induction of an anti-inflammatory phenotype that leads to a rapid reversal of clinical symptoms. The capacity of low doses of X-rays to suppress inflammatory responses is a significant new concept for treatment COVID-19 pneumonitis. Low dose whole lung irradiation may be a potential solution in the present time. International research organization and the International Geriatric Radiotherapy Group (http://www.igrg.org) proposed a simple and practical protocol for Low dose whole lung irradiation to allow participation of all countries in the world regardless of their resources and made available to the whole world community for treatment COVID-19 pneumonitis.